Email Updates

You are here

Home»Media

AVAC in the News

  • 48th Union World Conference: Good participatory practice guidelines come to TB vaccine development

    Describing the value of working with funders, sponsors, industry partners, governments and community members during all stages of tuberculosis vaccine research and development, the Good Participatory Practice Guidelines for TB Vaccine Research released the first day of this conference is the latest step in a movement to ensure those most affected by science inform its discoveries.

    October 17, 2017
    General
    Science Speaks

  • IDWeek 2017 HIV Science Preview

    With the annual IDWeek conference fast approaching, thousands of leading physicians and researchers will once again gather to learn about cutting-edge research on HIV prevention, treatment and cures—and to discuss how to apply that research in ways that can directly benefit people living with HIV today.

    September 29, 2017
    HIV Vaccine, Cure, PrEP
    BodyPro

  • Progress Reported on Monthly HIV Shot

    A clinical trial published in the Lancet showed a new injectable antiretroviral therapy (ART) given every four or eight weeks may be just as effective as the daily oral medications that are currently used to keep the virus under control.

    August 17, 2017
    PrEP
    Healthline

  • How a Blue Pill Is Stopping the Spread of HIV

    Thirty-six years after a rare lung infection in gay men in Los Angeles heralded the start of the AIDS epidemic, more than half of all people living with HIV are on virus-suppressing treatment. And thousands of people are using Gilead Sciences’ Truvada in a PrEP trial that’s curbing the spread in communities from London to San Francisco.

    August 17, 2017
    PrEP
    Bloomberg

  • PrEP Trials: The benefits—and challenges—of seeking community input

    Last fall, Gilead came under fire from community activists for rolling out the DISCOVER trials for Descovy (TAF/FTC) as PrEP without adequately involving community advisors per the Good Participatory Practice (GPP) guidelines. Community advocate and clinical investigator pushback led to some changes in the trial protocol, [but]...according to Jeremiah Johnson, community engagement coordinator for Treatment Action Group (TAG),...other concerns remain.

    August 7, 2017
    PrEP
    The Body

  • J&J Moves One Step Closer to a Potential Vaccine for HIV

    Healthcare giant Johnson & Johnson is to take a big step closer to inventing a vaccine for HIV when it publishes the results of a groundbreaking clinical trial this week.

    July 23, 2017
    HIV Vaccine
    Telegraph

  • What's Changed Since the Last HIV Meeting?

    As the world's top HIV experts head to Paris for an International AIDS Society meeting, word is we're still playing catch-up with the virus. And if resistance to antiretroviral drugs grows, things will only get worse.

    July 20, 2017
    Treatment
    Deutsche Welle

  • AIDS Deaths are Almost Half of What They Were in 2005 — But Experts Worry Trump Could Reverse That

    A new report from the United Nations shows promising progress in treating the global HIV/AIDS crisis, but some experts worry President Donald Trump’s policy proposals might turn the trend right back around.

    July 20, 2017
    Mic

  • Threatened HIV Funding Cuts in Limelight at IAS 2017

    Researchers, clinicians, and advocates converging in Paris for the International AIDS Conference 2017 will not only be talking about new HIV treatment and prevention and how to roll out innovative medications in a comprehensive, integrated way, they will also be making a case to funders...."If funders feel the progress we're making, it will create dividends in more ways than one," said International AIDS Society President Linda-Gail Bekker. "We may see some threatened cuts put on hold."

    July 19, 2017
    Medscape

  • Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists

    The surprise approval of generic Truvada (tenofovir disoproxil fumarate and emtricitabine) by the US Food and Drug Administration (FDA) on June 9 left patients, advocates and doctors scrambling to understand exactly when the generic will become available and how much it will cost.

    July 6, 2017
    PrEP
    The Body

Pages